{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '9. Anticipated life expectancy >12 weeks', '10. Willing and able to comply with clinic visits and study-related procedures', '11. Provide signed informed consent', '12. Able to understand and complete study-related questionnaires', '13. Patients must meet at least one of the following criteria regarding prior bevacizumab therapy:', 'a. Received prior bevacizumab-containing therapy, which was discontinued due to', 'progression of disease', 'b. Received prior bevacizumab-containing therapy, which was discontinued due to', 'toxicity', 'c.', 'Was deemed unsuitable for prior bevacizumab therapy for one of the following reasons:', '(i) unacceptable risk of fistula formation, (ii) poorly controlled hypertension, (iii) \"low', 'risk\" disease according to the Moore Criteria (Tewari 2015)', 'd. Refused prior bevacizumab therapy', 'e. Did not have access to bevacizumab therapy due to logistical reasons (eg, lived in a', 'region in which bevacizumab was not commercially available for patients with cervical', 'cancer, or did not have insurance coverage for bevacizumab)', '14. Patients must meet at least one of the following criteria regarding prior paclitaxel therapy:', 'a. Received prior paclitaxel-containing therapy, which was discontinued due to', 'progression of disease', 'b. Received prior paclitaxel-containing therapy, which was discontinued due to toxicity', 'c.', 'Was deemed unsuitable for prior paclitaxel therapy for one of the following reasons:', '(i) neuropathy (ii) allergy to paclitaxel or its components', 'd. Refused prior paclitaxel therapy', '6.2.2.', 'Exclusion Criteria', 'A patient who meets any of the following criteria will be excluded from the study:', '1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required', 'treatment with systemic immunosuppressive treatments, which may suggest higher risk for', 'severe irAEs. The following are not exclusionary: vitiligo, childhood asthma that has', 'resolved, type 1 diabetes, residual hypothyroidism that required only hormone replacement,', 'or psoriasis that does not require systemic treatment.', '2. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.', '3. Prior treatment with other systemic immune-modulating agents that was (a) within fewer', 'than 4 weeks (28 days) of the enrollment date, or (b) associated with irAEs of any grade', 'within 90 days prior to enrollment, or (c) associated with toxicity that resulted in', 'discontinuation of the immune-modulating agent. Examples of immune-modulating include', 'therapeutic vaccines, cytokine treatments (other than granulocyte colony stimulating factor', 'or erythropoietin), or agents that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), 4-1BB', '(CD137), PI 3-K-delta, LAG3, or OX-40.', '4. Known history of brain metastasis(es) that may be considered active (screening imaging of', 'brain is not required unless there is clinical suspicion of brain metastases). Patients with', 'Regeneron Pharmaceuticals, Inc.', 'Page 49 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'previously treated brain metastases may participate provided that the lesions are stable', '(without evidence of progression for at least 6 weeks on imaging obtained during the', 'screening period), there is no evidence of new or enlarging brain metastases, and the patient', 'does not require any immunosuppressive doses of systemic corticosteroids for management', 'of brain metastases within 4 weeks of the first dose of study drug (cemiplimab or IC chemo).', '5.', 'Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within', '4 weeks prior to the first dose of study drug (cemiplimab or IC chemo).', 'NOTE: Patients who require brief courses of steroids (eg, as prophylaxis for imaging', 'studies due to hypersensitivity to contrast agents) are not excluded.', '6. Active bacterial, viral, fungal or mycobacterial infection requiring therapy, including known', 'infection with human immunodeficiency virus (HIV), or active infection with hepatitis B', 'virus (HBV) or hepatitis C virus (HCV).', 'NOTE: Active infection with HBV is defined as having positive surface antigen.', '7. History of pneumonitis within the last 5 years.', 'NOTE: Pneumonitis is inclusive of interstitial pneumonitis and active, non-infectious', 'pneumonia, including interstitial lung disease.', '8. Any anticancer treatment (chemotherapy, targeted systemic therapy, photodynamic therapy),', 'investigational, or standard of care, within 30 days of the initial administration of study drug', '(cemiplimab or IC chemo) or planned to occur during the study period (patients receiving', 'bisphosphonates or denosumab are not excluded).', 'NOTE: Any radiation therapy must be discontinued at least 14 days prior to initial', 'administration of study drug (cemiplimab or IC chemo).', '9.', 'History of documented allergic reactions or acute hypersensitivity reaction attributed to', 'antibody treatments.', '10. Criterion deleted in Amendment 3.', '11. Concurrent malignancy other than cervical cancer and/or history of malignancy other than', 'cervical cancer within 3 years of date of first planned dose of study drug (cemiplimab or IC', 'chemo), except for tumors with negligible risk of metastasis or death, such as adequately', 'treated cutaneous squamous cell carcinoma or basal cell carcinoma of the skin or ductal', 'carcinoma in situ of the breast. Patients with hematologic malignancies (eg, chronic', 'lymphocytic leukemia) are excluded.', '12. Any acute or chronic psychiatric problems that, in the opinion of the investigator, make the', 'patient ineligible for participation.', '13. Patients with a history of solid organ transplant (patients with prior corneal transplant(s) may', 'be allowed to enroll after discussion with and approval from the medical monitor).', '14. Any medical co-morbidity, physical examination finding, or metabolic dysfunction, or', 'clinical laboratory abnormality that, in the opinion of the investigator, renders the patient', 'unsuitable for participation in a clinical trial due to high safety risks and/or potential to affect', 'interpretation of results of the study.', 'Regeneron Pharmaceuticals, Inc.', 'Page 50 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}